<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00473057</url>
  </required_header>
  <id_info>
    <org_study_id>CONEP-10385</org_study_id>
    <secondary_id>CEP-HUCFF/UFRJ-169/03</secondary_id>
    <secondary_id>Proc.-CNPq-55.2201/2005-7</secondary_id>
    <nct_id>NCT00473057</nct_id>
  </id_info>
  <brief_title>Study of Autologous Stem Cell Transplantation for Patients With Ischemic Stroke</brief_title>
  <official_title>Phase I Study of Autologous Bone Marrow Cell Transplantation in Patient With Ischemic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Science and Technology, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ministry of Health, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Brazil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open label study to assess the safety of autologous bone marrow transplantation in
      patients with a ischemic stroke in the middle cerebral artery territory within 90 days from
      symptoms onset.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: The purpose of this study is to evaluate the safety and feasibility of
      intra-arterial and intravenous injection of autologous bone marrow mononuclear cells in
      patients in the acute and sub-acute phase (&gt; 3 and &lt; 90 days after symptoms onset) of
      ischemic cerebral infarct in the middle cerebral artery territory.

      Methods: 15 patients with cerebral infarct within the middle cerebral artery territory will
      be enrolled in this prospective, nonrandomized, open-labeled study. Up to 10 patients will
      receive up to 500x 10 6 autologous bone marrow cells injected intra-arterially into the
      middle cerebral artery through percutaneous approach. The procedure is monitored by
      Transcranial Doppler (TCD) and electroencephalogram (EEG). Other 5 patients will receive up
      to 500x 10 6 autologous bone marrow cells injected intravenously. Changes in neurological
      deficits and improvements in functions will be evaluated at baseline and at regular intervals
      during follow-up ( 4 months). EEG and neuroimaging exams will be performed at baseline and at
      regular intervals during the follow-up period.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absence of new neurological deficits during the procedure and/or in the 4 months follow-up.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of neurological deficits</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in the neuroimaging exams</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">12</enrollment>
  <condition>Infarction, Middle Cerebral Artery</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Autologous cell transplantation</intervention_name>
    <description>Intra-arterial or intravenous delivery of autologous bone marrow cells</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  clinical diagnosis of ischemic stroke lasting for more than 3 hours and less than 90
             days from symptoms onset

          -  neuroimages exams showing ischemic cerebral infarct in the middle cerebral artery
             territory

          -  age between 18 and 75 years old

          -  NIHSS between 4 and 20

          -  spontaneous re-canalization of the middle cerebral artery documented by TCD or MRI

          -  signed informed consent

        Exclusion Criteria:

          -  difficult in obtaining vascular access for percutaneous procedures

          -  vascular impossibility to reach the middle cerebral artery through percutaneous
             approach

          -  severe carotid stenosis( &gt;70%, by Doppler) related to the severe stroke

          -  neurological worsening (&gt;4 points in the NIHSS ) due to edema or intracerebral
             hemorrhage

          -  primary hematological disease

          -  neurodegenerative disorder

          -  previous stroke with mRS &gt; 2

          -  intracardiac thrombosis

          -  auto-imune disorders

          -  osteopathies that could increase the risk of bone marrow harvesting procedure

          -  thrombophilias

          -  liver failure

          -  chronic renal failure (creatinine &gt; 2mg/ml)

          -  life support dependence

          -  lacunar stroke

          -  pregnancy

          -  history of neoplasia or other comorbidity that could impact patient's short-term
             survival

          -  any condition that in the judgment of the investigator would place the patient under
             undue risk
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles André, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabriel R de Freitas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rosalia Mendez-Otero, Md, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lea Mirian Barbosa da Fonseca, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Universitário Clementino Fraga Filho/UFRJ</name>
      <address>
        <city>Rio de Janeiro</city>
        <state>RJ</state>
        <zip>21.941-590</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 10, 2007</study_first_submitted>
  <study_first_submitted_qc>May 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <last_update_submitted>May 18, 2011</last_update_submitted>
  <last_update_submitted_qc>May 18, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 19, 2011</last_update_posted>
  <responsible_party>
    <name_title>Charles Andre, MD, PhD</name_title>
    <organization>Universidade Federal do Rio de Janeiro</organization>
  </responsible_party>
  <keyword>acute stroke</keyword>
  <keyword>middle cerebral artery</keyword>
  <keyword>autologous transplantation</keyword>
  <keyword>bone marrow cells</keyword>
  <keyword>stem cells</keyword>
  <keyword>cell therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Infarction, Middle Cerebral Artery</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

